Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Fever; Aphasia; Cranial nerve decompression; Hemiparesis; Accident cerebrovascular; Cerebral haemorrhage; Loss of consciousness; This is a spontaneous report downloaded from the Regulatory Authority [Regulatory Authority Number DE-PEI-CADR2021018615]. A contactable consumer or other non-HCP reported that an 82-year-old female patient received the first dose of BTN162b2 (CORMINATY, Lot number unknown) intramuscularly on 05Feb2021 at single dose for COVID-19 immunisation. Relevant medical history included ongoing permanent atrial fibrillation, ongoing hypertension, ongoing coagulation factor inhibition test and COVID-19 in Dec2020. It was also reportedthat the patient had HLP. The patient had COVID-19 infection with typical symptoms and a positive PCR test in Dec2020. No concomitant medications were reported, but it was mentioned that the patient was on anticoagulation with Eliquis. On 10Feb2021 the patient experienced loss of consciousness, stroke, hemiparesis, cerebral haemorrhage, decompression of the cranial nerve. It was reported that there was acute briefing on 10Feb2021 with malignant stroke ACM right with hemiplegia left and global aphasia as well as fever. Cause of death was reported as apoplectic fit. Outcome for loss of consciousness was reported as not resolved, while it was fatal for stroke, hemiparesis, cerebral haemorrhage and decompression of the cranial nerve. Outcome of the other event was unknown. It was unknown whether an autopsy was performed. No follow-up attempts are possible, information about lot/batch number cannot be obtained.; Reported Cause(s) of Death: Apoplectic fit/Accident cerebrovascular; Cranial nerve decompression; Hemiparesis; Cerebral haemorrhage
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166